Solve ME/CFS Initiative

Solve M.E. Awarded Grant From Chan Zuckerberg Initiative to Support Patient Engagement in Long Covid Research

Retrieved on: 
Tuesday, December 13, 2022
PASC, Trust, Publication, COVID-19, COVID-19 policy of the Joe Biden administration, Food, Survivor, Human, Government, Chan Zuckerberg Initiative, Research, Patient, Curriculum, Myalgia, Solve, Knowledge, Disease, FDA, Drug development, Caregiver, Education, CZI, Food and Drug Administration Amendments Act of 2007, ME/CFS, M.E, Solve ME/CFS Initiative, Pharmaceutical industry, Long COVID, Science

LOS ANGELES, Dec. 13, 2022 /PRNewswire/ -- Today, Solve M.E. announced it is the recipient of significant grant funding from the Chan Zuckerberg Initiative (CZI). With the $247,500 in funding, Solve M.E. will develop a groundbreaking program that will train a network of patient leaders, scientists and other stakeholders with diverse backgrounds to enhance patient engagement in Long Covid research. These trained patient representatives will ultimately create a targeted research agenda, a network of empowered patient-advocates and a guide to working with Long Covid patients for researchers. These critical tools will provide urgently needed guidance on achieving patient-centered research in the Long Covid field, as well as help to empower communities in other related fields.

Key Points: 
  • will develop a groundbreaking program that will train a network of patient leaders, scientists and other stakeholders with diverse backgrounds to enhance patient engagement in Long Covid research.
  • These trained patient representatives will ultimately create a targeted research agenda, a network of empowered patient-advocates and a guide to working with Long Covid patients for researchers.
  • In key publications, like the National Research Action Plan on Long Covid 3and the recent Health+ Long Covid report 4, patient contributions have been vital.
  • to solve Long Covid and associated conditions, as well as participating in research and joining in advocacy and awareness efforts.

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Retrieved on: 
Wednesday, October 12, 2022
Method, Lists of diseases, Physician, Solve ME/CFS Initiative, American, Disease, Therapy, PSLRA, Fatigue, IND, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, Solve, AIM, Parallel Walk Test, Long, Knowledge, Private Securities Litigation Reform Act, Food, Immune system, Trial of the century, Company, Doctor of Philosophy, Myalgia, Degenerative disease, CEO, Patent, Safety, GLOBE, PLOS, Clinical trial, Government, Running, FDA, COVID-19, ME/CFS, Cancer, M.E, Pharmaceutical industry, Long COVID, Rintatolimod

AIM has pending patent applications for compositions and methods for treating post-COVID conditions with a composition comprising Ampligen.

Key Points: 
  • AIM has pending patent applications for compositions and methods for treating post-COVID conditions with a composition comprising Ampligen.
  • Post-COVID-19 Disabling Fatigue, along with other debilitating post-COVID conditions such as Brain Fog, continue to affect tens of millions of people worldwide.
  • The planned Phase 2 study is a two-arm, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of Ampligen in patients experiencing the post-COVID condition of fatigue.
  • Significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment for Long COVID.

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Retrieved on: 
Wednesday, October 12, 2022
Method, Lists of diseases, Physician, Solve ME/CFS Initiative, American, Disease, Therapy, PSLRA, Fatigue, IND, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, Solve, AIM, Parallel Walk Test, Long, Knowledge, Private Securities Litigation Reform Act, Food, Immune system, Trial of the century, Company, Doctor of Philosophy, Myalgia, Degenerative disease, CEO, Patent, Safety, GLOBE, PLOS, Clinical trial, Government, Running, FDA, COVID-19, ME/CFS, Cancer, M.E, Pharmaceutical industry, Long COVID, Rintatolimod

AIM has pending patent applications for compositions and methods for treating post-COVID conditions with a composition comprising Ampligen.

Key Points: 
  • AIM has pending patent applications for compositions and methods for treating post-COVID conditions with a composition comprising Ampligen.
  • Post-COVID-19 Disabling Fatigue, along with other debilitating post-COVID conditions such as Brain Fog, continue to affect tens of millions of people worldwide.
  • The planned Phase 2 study is a two-arm, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of Ampligen in patients experiencing the post-COVID condition of fatigue.
  • Significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment for Long COVID.

SOLVE M.E. LAUNCHES THE FIRST NATIONWIDE PSA CAMPAIGN TO BROADEN AWARENESS OF LONG COVID

Retrieved on: 
Wednesday, August 17, 2022
PSA, How Long, Social change, NIH, Industry, CEO, Capitol Hill, POTS, Solve, Brain, Learning, ME/CFS, National, Entertainment Industry Foundation, Congress, How Long (Charlie Puth song), Research, Hope, M.E, Human, Government, Lyme disease, Patient, Fatigue, COVID-19, EIF, Initiative, Education, Partnership, Conditional sentence, Myalgia, Awareness, Empathy, Solve ME/CFS Initiative, MCAS, Mast cell activation syndrome, Postural orthostatic tachycardia syndrome, Disease, Pharmaceutical industry, Long COVID

LOS ANGELES, Aug. 15, 2022 /PRNewswire/ -- Solve M.E. has released the first nationwide public service announcement (PSA) campaign titled "How Long?" to broaden awareness of Long Covid and highlight the need for more research to adequately help the many patients affected by this debilitating disease, which could last a lifetime.

Key Points: 
  • has released the first nationwide public service announcement (PSA) campaign titled " How Long? "
  • has released a PSA campaign to broaden awareness of Long Covid and highlight the need for more research.
  • Over 20 million Americans are suffering from Long Covid , and Long Covid could account for 15% of the nation's unfilled jobs.
  • campaign, support our work to solve Long Covid and associated conditions, learn more about participating in research, and join our advocacy efforts.

WORLDWIDE LAUNCH OF "LONG HAUL VOICES: LIVING WITH LONG COVID AND ME/CFS" RELEASED TODAY IN HONOR OF WORLD ME DAY 2022

Retrieved on: 
Thursday, May 12, 2022
Population, Solve ME/CFS Initiative, Multimedia, Conditional sentence, COVID-19, M.E, MCAS, Solve, Caregiver, Research, CRPS, FDA, Unfixable, Partnership, Government, Disability, MS, Instagram, Human, Congress, Myalgia, Labyrinthitis, Twitter, WITH, Prevalence, POTS, ME/CFS, CEO, Animal, Pharmaceutical industry, Long COVID, Autism, Facebook

LOS ANGELES, May 12, 2022 /PRNewswire/ -- Today, in honor of World ME Day, Solve M.E. released the first episode of a three-part series: Long Haul Voices: Living with Long Covid and ME/CFS. Long Haul Voices seeks to amplify globally the experiences of individuals with Long Covid and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), the experts devoted to improving their care, and the challenges surrounding these largely invisible, poorly-understood diseases that affect a rapidly growing population. Access the series here.

Key Points: 
  • released the first episode of a three-part series: Long Haul Voices: Living with Long Covid and ME/CFS .
  • WORLDWIDE LAUNCH OF LONG HAUL VOICES: LIVING WITH LONG COVID AND ME/CFS RELEASED TODAY IN HONOR OF WORLD ME DAY 2022
    "Long Haul Voices highlights how people with ME/CFS and Long Covid can share their journey to improve the management and understanding of these diseases across the world," said Oved Amitay, president and CEO, Solve M.E.
  • honors the core theme of this year's World ME Day: 'What Can the World #LearnFromME?'"
  • Each featured member of the Long Haul Voices cast shares a connection to ME/CFS and/or Long Covid.

AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022

Retrieved on: 
Thursday, May 12, 2022
Cancer, Rintatolimod, Global Interdependence Center, Company, Disease, Solve ME/CFS Initiative, Private Securities Litigation Reform Act, ME/CFS, Research, American, Science, Patient, COVID-19, PSLRA, Solve, Partnership, Lists of diseases, Awareness, AIM, Government, EAP, RNA, Myalgia, Degenerative disease, Therapy, Immune system, COVID, NYSE, GLOBE, Pharmaceutical industry, Vaccine, Long COVID, Policy

Diagnostics signature event Long COVID: Research, Policy, and Economic Impact , being held virtually and in New York, N.Y. on Thursday, May 19, 2022.

Key Points: 
  • Diagnostics signature event Long COVID: Research, Policy, and Economic Impact , being held virtually and in New York, N.Y. on Thursday, May 19, 2022.
  • The Global Interdependence Center, in partnership with the Solve Long Covid Initiative, is continuing its conference series exploring the pandemics long-term healthcare, policy, and economic impact, specifically the implications of long haul COVID (a.k.a.
  • The event is aimed at raising awareness of Long Covid by examining the science and research behind it.
  • Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA.

Streaming Channel Teams Up With Award-Winning Filmmaker to Debut Series About Life With Long Covid Plus Rare Disease

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, Population, Ehlers–Danlos syndromes, Disorder, The Man Who Turned to Stone, GLOBE, Palliative care, Guide book, Solve, Depression, Solve ME/CFS Initiative, Patient, FOP, Partnership, Caregiver, Disability, Degenerative disease, Flight length, Alnylam Pharmaceuticals, Fibrodysplasia ossificans progressiva, Rare disease, Disease, Lists of diseases, Roku, Fire, Pharmaceutical industry, Takeda, Health

FALMOUTH, Maine, May 10, 2022 (GLOBE NEWSWIRE) -- The Disorder Channel, a free streaming channel for rare disease stories on TV, is uniting with nonprofit The Solve ME/CFS Initiative (Solve M.E.)

Key Points: 
  • FALMOUTH, Maine, May 10, 2022 (GLOBE NEWSWIRE) -- The Disorder Channel, a free streaming channel for rare disease stories on TV, is uniting with nonprofit The Solve ME/CFS Initiative (Solve M.E.)
  • Before contracting long Covid, two of those featured in the series already had rare diseases: Ehlers-Danlos Syndrome and complex regional pain syndrome.
  • Episodes of this series will debut exclusively on The Disorder Channel beginning May 5.
  • The Disorder Channel is the only streaming channel devoted to programming about rare diseases.

THE WIDESPREAD IMPACT OF LONG COVID CONTINUES TO GROW, SHINING AN EVEN BRIGHTER LIGHT ON MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS)

Retrieved on: 
Monday, May 2, 2022
COVID-19, Population, Instagram, Twitter, ME/CFS, LC, Capitol Hill, Engagement, Solve, Solve ME/CFS Initiative, DLC, Caregiver, Government, Myalgia, Conditional sentence, Research, M.E, Multimedia, Animal, Pharmaceutical industry, Long COVID, Facebook

LOS ANGELES, May 2, 2022 /PRNewswire/ -- As the prevalence and significant impact of Long Covid continues to increase, the number of people suffering from the debilitating and chronic illness known as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) parallels this growth. Solve M.E. and its partners will spend May advocating for people with ME/CFS, Long Covid, and other chronic diseases, to ensure that ME/CFS and other post-infection diseases are widely understood, diagnosable, and treatable.

Key Points: 
  • A recently released whitepaper by the Solve Long Covid Initiative spotlights the staggering economic impact of Long Covid:
    22 million U.S. adults are living with Long Covid (LC) close to 7% of the population.
  • 7 million are experiencing Disabling Long Covid (DLC) 2.3% of the population.
  • "Long COVID and debilitating, chronic diseases directly impact our communities," said Emily Taylor, Vice President of Advocacy and Engagement, Solve M.E.
  • is a non-profit organization that serves as a catalyst for critical research into diagnostics, treatments, and cures for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long Covid, and other post-infection diseases.

AIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar

Retrieved on: 
Wednesday, January 26, 2022
AIM, AIM ImmunoTech, ME/CFS, COVID-19, Medicine, Solve ME/CFS Initiative, PSLRA, Research, Therapy, Private Securities Litigation Reform Act, Solve, American, Disease, Company, Cancer, Degenerative disease, EAP, Patient, Rintatolimod, Myalgia, Immune system, Government, NYSE, GLOBE, Lists of diseases, Pharmaceutical industry, Vaccine, Long COVID

OCALA, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced it will participate in the Solve M.E. Diagnostics and Treatments Webinar: “Ampligen: A General Overview and the Plan for ME/CFS & Long Covid,” being held on Thursday, January 27, 2022 from 2:00 – 3:00 pm ET. Ampligen (rintatolimod), is AIM’s RNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is designed to modulate the immune system and has demonstrated anti-viral activity. The Company is currently sponsoring an expanded access program (EAP) for ME/CFS patients in the United States, and in 2021, AIM dosed its first “Long Hauler” patient with Ampligen in its post-COVID-19 “Long Hauler” portion of the active AMP-511 EAP in the U.S. Early data from the ongoing AMP-511 EAP and data from an earlier study, AMP-502, has indicated that patients with cognitive function deficiency have reported improvements in cognitive function after Ampligen treatment.

Key Points: 
  • Diagnostics and Treatments Webinar: Ampligen: A General Overview and the Plan for ME/CFS & Long Covid , being held on Thursday, January 27, 2022 from 2:00 3:00 pm ET.
  • Ampligen (rintatolimod), is AIMs RNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
  • As part of the webinar hosted by Solve, Thomas K. Equels, M.S., J.D., Chief Executive Officer of AIM ImmunoTech and David R. Strayer, M.D., Chief Scientific & Medical Officer of AIM ImmunoTech will join Solve President and CEO Oved Amitay to discuss the clinical development plans for Ampligen for the treatment of ME/CFS and Long COVID.
  • The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Chronic Disease Stakeholders Join SOLVE M.E. in Push for Federally Funded Research into Long COVID

Retrieved on: 
Friday, December 4, 2020
Medicine, Health, Chronic fatigue syndrome, Solve ME/CFS Initiative, Long Covid, Centers for Disease Control and Prevention, Coronavirus disease, Chronic condition

LOS ANGELES, Dec. 4, 2020 /PRNewswire/ --Twenty leading chronic disease stakeholders joined the Solve ME/CFS Initiative (Solve M.E.)

Key Points: 
  • LOS ANGELES, Dec. 4, 2020 /PRNewswire/ --Twenty leading chronic disease stakeholders joined the Solve ME/CFS Initiative (Solve M.E.)
  • in authoring a powerful letter urging Congress to fund millions of dollars in new National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) research into the post-viral health complications for long-term COVID-19 (Long COVID) survivors.
  • "Preliminary evidence suggests that nearly five million Americans will experience Long COVID regardless of infection severity, which will likely result in a post-viral chronic fatigue crisis," said Oved Amitay, CEO of Solve M.E.
  • These alarming statistics underscore the urgent need for funding, research, diagnostics, and treatment into Long COVID.